GC
VKTX icon

Guggenheim Capital’s Viking Therapeutics VKTX Stock Holding History

Guggenheim Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
36,816
+1,924
+6% +$62.1K 0.01% 857
2026
Q1 		$1.14M Buy
34,892
+5,173
+17% +$166K 0.01% 944
2025
Q4 		$1.05M Sell
29,719
-2,960
-9% -$105K 0.01% 928
2025
Q3 		$859K Buy
32,679
+2,064
+7% +$61.6K 0.01% 971
2025
Q2 		$811K Sell
30,615
-243
-0.8% -$6.4K 0.01% 965
2025
Q1 		$745K Buy
30,858
+5,519
+22% +$174K 0.01% 1015
2024
Q4 		$1.02M Buy
25,339
+142
+0.6% +$8.1K 0.01% 911
2024
Q3 		$1.6M Sell
25,197
-2,613
-9% -$153K 0.01% 899
2024
Q2 		$1.47M Buy
+27,810
New +$1.82M 0.01% 931
2018
Q2 		– Sell
-11,988
Closed -$52K – 2612
2018
Q1 		$52K Buy
+11,988
New +$66.3K ﹤0.01% 2707
2017
Q4 		– Sell
-10,366
Closed -$20K – 2815
2017
Q3 		$20K Buy
+10,366
New +$11.8K ﹤0.01% 2748

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Guggenheim Capital's VKTX Position: Q2 2026 in Review

Guggenheim Capital increased its Viking Therapeutics (VKTX) stake by 5.5% in Q2 2026, buying an estimated $62.1K and bringing the position to 36,816 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #857.

Guggenheim Capital first reported a position in VKTX in Q3 2017 and has held it in 11 quarters since. The position peaked at $1.6M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Guggenheim Capital held 36,816 shares of Viking Therapeutics worth $1.44M as of Q2 2026.
  • Guggenheim Capital bought 1,924 Viking Therapeutics shares in Q2 2026, an estimated $62.1K.
  • Viking Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #857 holding.
  • Guggenheim Capital first reported a position in Viking Therapeutics in Q3 2017 and has held it in 11 quarters since.
  • Guggenheim Capital's Viking Therapeutics position peaked at $1.6M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.